Increase in serum DKK1 levels attenuates the anabolic response to romosozumab in postmenopausal osteoporosis
Authors' conclusion
Romosozumab treatment is associated with a significant rise in Dkk1 levels, which correlates with a decrease in bone formation markers over time.
Study context
- Population
- Postmenopausal osteoporosis naïve to anti-osteoporosis treatment, treated with romosozumab
- Outcome
- Association between Dkk1 and P1NP (linear mixed-effects models)
Methodological details12-mo, single-arm
- 12-mo
- Single-arm
Main finding
As reported in the abstract
M0 to M12
- Dkk1 increased from 38.9 pmol/L at M0 to 44.2 pmol/L at M12
- p = .003
- Inverse association between Dkk1 increase and P1NP decrease between M3 and M12
- estimate = −0.909; p = .032
Observational data: associations, not effects.
Further findings
P1NP · M0, M3, M12
- P1NP increased from 89.4 ng/mL at M0 to 115.4 ng/mL at M3
- P = 0.004
- P1NP decreased to 61.5 ng/mL by M12
- P < 0.001
CTX · throughout study
- CTX decreased significantly throughout the study
- P < 0.001
BMD change · M12
- LS
- + 13.8%
- FN
- + 6.3%
- TH
- + 4.7%
- All sites
- all p < .01
Original publication
Increase in serum DKK1 levels attenuates the anabolic response to romosozumab in postmenopausal osteoporosis. J Bone Miner Res. Published 19 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →